These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 36252471

  • 21. Controversies in central nervous system prophylaxis of high-risk diffuse large B-cell lymphoma.
    Bobillo S, Wilson MR, Cwynarski K.
    Curr Opin Oncol; 2023 Sep 01; 35(5):382-388. PubMed ID: 37551947
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Timing of high-dose methotrexate CNS prophylaxis in DLBCL: an analysis of toxicity and impact on R-CHOP delivery.
    Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J, Mula Kh A, Shah N, Cheung CK, Timmins MA, Creasey T, Linton K, Smith J, Fox CP, Miall F, Cwynarski K, McKay P.
    Blood Adv; 2020 Aug 11; 4(15):3586-3593. PubMed ID: 32761231
    [Abstract] [Full Text] [Related]

  • 24. Primary breast diffuse large B-cell lymphoma in the rituximab era: A retrospective study of the Chinese Southwest Oncology Group.
    Weng H, Shrestha PR, Hong H, Chen Z, Yu L, Yao Y, Zhang Z, Zou L, Zhu B, Zhou H, Liu X, Liu Y, Guo H, Huang H, Lin T.
    Cancer Med; 2023 Dec 11; 12(23):21188-21198. PubMed ID: 37997571
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse.
    Goldschmidt N, Horowitz NA, Heffes V, Darawshy F, Mashiach T, Shaulov A, Gatt ME, Dann EJ.
    Leuk Lymphoma; 2019 Aug 11; 60(8):1890-1898. PubMed ID: 30689468
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
    Holte H, Leppä S, Björkholm M, Fluge O, Jyrkkiö S, Delabie J, Sundström C, Karjalainen-Lindsberg ML, Erlanson M, Kolstad A, Fosså A, Ostenstad B, Löfvenberg E, Nordström M, Janes R, Pedersen LM, Anderson H, Jerkeman M, Eriksson M.
    Ann Oncol; 2013 May 11; 24(5):1385-92. PubMed ID: 23247661
    [Abstract] [Full Text] [Related]

  • 31. Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma.
    Kuitunen H, Kaprio E, Karihtala P, Makkonen V, Kauppila S, Haapasaari KM, Kuusisto M, Jantunen E, Turpeenniemi-Hujanen T, Kuittinen O.
    Ann Hematol; 2020 Aug 11; 99(8):1823-1831. PubMed ID: 32577843
    [Abstract] [Full Text] [Related]

  • 32. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis.
    Zhang J, Chen B, Xu X.
    Leuk Lymphoma; 2014 Mar 11; 55(3):509-14. PubMed ID: 23741977
    [Abstract] [Full Text] [Related]

  • 33. Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of intravenous high-dose methotrexate CNS prophylaxis and the importance of baseline cerebrospinal fluid analysis.
    Bennett R, Ruskova A, Coomarasamy C, Theakston E, Berkahn L, Jackson S, Christophers M, Wong S, Issa S.
    Am J Hematol; 2023 Jul 11; 98(7):1070-1079. PubMed ID: 37161765
    [Abstract] [Full Text] [Related]

  • 34. Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma.
    Puckrin R, El Darsa H, Ghosh S, Peters A, Owen C, Stewart D.
    Am J Hematol; 2021 Jul 01; 96(7):764-771. PubMed ID: 33811794
    [Abstract] [Full Text] [Related]

  • 35. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
    Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T.
    Clin Lymphoma Myeloma Leuk; 2015 Aug 01; 15(8):451-7. PubMed ID: 25816933
    [Abstract] [Full Text] [Related]

  • 36. Secondary central nervous system involvement in 599 patients with diffuse large B-cell lymphoma: are there any changes in the rituximab era?
    Deng L, Song Y, Zhu J, Zheng W, Wang X, Xie Y, Lin N, Tu M, Ping L, Ying Z, Liu W, Zhang C.
    Int J Hematol; 2013 Dec 01; 98(6):664-71. PubMed ID: 24234713
    [Abstract] [Full Text] [Related]

  • 37. Optimization of high-dose methotrexate prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma: a multicenter analysis.
    Fang Y, Su N, Ma S, Cai J, Zhong L, Li W, Huang H, Li Z, Huang H, Xia Y, Liu P, Guo L, Li Z, Wu Y, Tian X, Wang J, Zhang Y, Cai Q.
    Ann Hematol; 2022 Mar 01; 101(3):595-605. PubMed ID: 34985557
    [Abstract] [Full Text] [Related]

  • 38. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
    Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA.
    Cancer; 2012 Jun 01; 118(11):2944-51. PubMed ID: 22006274
    [Abstract] [Full Text] [Related]

  • 39. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
    Sancho JM, Ribera JM, Working Group on Diagnosis, Prevention and Treatment of CNS Infiltration in Patients with DLBCL.
    Med Clin (Barc); 2016 Jan 15; 146(2):74-80. PubMed ID: 25817451
    [Abstract] [Full Text] [Related]

  • 40. About time: why central nervous system prophylaxis timing in diffuse large B-cell lymphoma matters and does the protocol need updating?
    Lewis KL, Cheah CY.
    Expert Rev Hematol; 2022 Nov 15; 15(11):959-962. PubMed ID: 36278876
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.